BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...investors included Hillhouse affiliate GL Ventures and GIC and existing investors Qiming Venture Partners and Boyu Capital...
BioCentury | Apr 23, 2020
Finance

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

...which prompted the international share re-allotment. Cornerstone investors including Fidelity Investments, Lake Bleu Prime, OrbiMed, Boyu Capital...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...LSE:AZN; NYSE:AZN) unit in 2018 with a $250 million series A led by Chinese firm Boyu Capital...
BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

...plc (LSE:AZN; NYSE:AZN) in 2018 with a $250 million series A led by Chinese firm Boyu Capital...
BioCentury | Jun 17, 2019
Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

...MedImmune unit of AstraZeneca plc (LSE:AZN; NYSE:AZN). The series A was led by Chinese firms Boyu Capital...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...2016 Asia top 5 rounds Curon Biopharmaceutical Ltd. Shanghai, China $150.0 6 Dimensions Capital , Boyu Capital...
BioCentury | Feb 15, 2019
Financial News

CStone could get $1.5B valuation in Hong Kong IPO

...funds managed by Indus Capital Partners LLC, GIC and its wholly owned subsidiary Tetrad Ventures, Boyu Capital...
BioCentury | Feb 14, 2019
Financial News

CStone could get $1.5B valuation in Hong Kong IPO

...funds managed by Indus Capital Partners LLC, GIC and its wholly owned subsidiary Tetrad Ventures, Boyu Capital...
BioCentury | Jan 4, 2019
Financial News

China's Antengene raises $120M series B round

...on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital...
BioCentury | Jan 2, 2019
Financial News

China's Antengene raises $120M series B round

...series B round to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital...
Items per page:
1 - 10 of 38
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...investors included Hillhouse affiliate GL Ventures and GIC and existing investors Qiming Venture Partners and Boyu Capital...
BioCentury | Apr 23, 2020
Finance

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

...which prompted the international share re-allotment. Cornerstone investors including Fidelity Investments, Lake Bleu Prime, OrbiMed, Boyu Capital...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...LSE:AZN; NYSE:AZN) unit in 2018 with a $250 million series A led by Chinese firm Boyu Capital...
BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

...plc (LSE:AZN; NYSE:AZN) in 2018 with a $250 million series A led by Chinese firm Boyu Capital...
BioCentury | Jun 17, 2019
Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

...MedImmune unit of AstraZeneca plc (LSE:AZN; NYSE:AZN). The series A was led by Chinese firms Boyu Capital...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...2016 Asia top 5 rounds Curon Biopharmaceutical Ltd. Shanghai, China $150.0 6 Dimensions Capital , Boyu Capital...
BioCentury | Feb 15, 2019
Financial News

CStone could get $1.5B valuation in Hong Kong IPO

...funds managed by Indus Capital Partners LLC, GIC and its wholly owned subsidiary Tetrad Ventures, Boyu Capital...
BioCentury | Feb 14, 2019
Financial News

CStone could get $1.5B valuation in Hong Kong IPO

...funds managed by Indus Capital Partners LLC, GIC and its wholly owned subsidiary Tetrad Ventures, Boyu Capital...
BioCentury | Jan 4, 2019
Financial News

China's Antengene raises $120M series B round

...on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital...
BioCentury | Jan 2, 2019
Financial News

China's Antengene raises $120M series B round

...series B round to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital...
Items per page:
1 - 10 of 38